The world s largest commercially-focused orphan drug event

Transcription

1 The world s largest commercially-focused orphan drug event The Mandarin Oriental Hotel Washington D.C. USA Expo dates: April 2013 Expo times: 10:00am-4:00pm PROMO CODE SPARE Book now for free at created by book now for free entry

2 20+ How to book for free Fast track your entry into the show! Pre-book your visitor pass and seminar attendance online at The global orphan drug meeting place The seminars How to benefit from patient registry collaborations How to raise funds How to find CMO experts with pre-determined processes How to design and manage your supply chain How to expedite orphan drug development through open science How to benefit from disposable technology How to discover orphan drugs through drug repositioning Patient Groups Principal Investigators & Scientists Government Who should attend Academia Procurement Managers Join the conversation Manufacturing Engineers & QA/ QC Managers Physicians & Hospitals #WODC linkd.in/omtk6g Investors THE wo larg orph drug e

3 Made valuable connections and left with ideas on how to better engage with patients. Enjoyed networking, presentations and attendance of senior leaders Steve Roberds CSO Tuberous Sclerosis Alliance World class exhibitors ld s est an vent Tools & technology Exhibitors will showcase Equipment & manufacturing Contract manufacturing Why visit? Contract research Consulting Legal services Diagnostics Free educational seminars to advance your expertise See the latest products, services and solutions Meet with the key suppliers shaping your industry Network, find partners, build relationships Discuss marketplace developments Stay ahead of your competitors IT software Win an ipad Stop by the Omnicare booth to enter their raffle for a mini 16GB ipad! Lots of fun activities and giveaways will be going on around the exhibition floor, so confirm your visitor pass today! It s and it s 2days free

4 DIAGNOSIS, TREATMENT & QUALITY OF LIFE 10:00 10: :30 How The Lam Foundation got academia, research institutes, industry and patients to work together Eugene Sullivan, Board Member, The LAM Foundation How to benefit from patient registry collaborations with the industry Steven L. Roberds, Chief Scientific Officer, Tuberous Sclerosis Alliance How Phelan-McDermid Syndrome Foundation structured their rare disease registry Megan O Boyle, Director, Phelan-McDermid Syndrome Foundation How to establish a relationship with physicians Rino Aldrighetti, President and Chief Executive Officer, Pulmonary Hypertension Association On-floor seminar day one Wednesday, April 10, MANUFACTURING, QUALITY CONTROL AND QUALITY ASSURANCE How Genzyme overcame manufacturing challenges Sandra Poole, Senior Vice President, Biologics Operations and Allston Site Head, Genzyme How to find CMO experts with pre-determined processes Allen Ritter, Vice President, Manufacturing/CMC, Endocyte How to design and manage your supply chain from an orphan drug manufacturing perspective Jayant Aphale, Senior Vice President, Technical Operations, Sarepta Therapeutics PRINCIPAL INVESTIGATORS AND SCIENTISTS CHALLENGES IN ORPHAN DRUG DISCOVERY How to do better research studies lessons learned from Duchenne Eric Hoffman, Director, Research Center for Genetic Medicine, Children s National Medical Center How to expedite orphan drug development through open science Joseph Jackson III, Founder, Open Science Movement How to fast-track approvals for orphan drugs in early stage development Celine Plisson, Associate Medical Director, Orphan Europe End of day one

5 DIAGNOSIS, TREATMENT & QUALITY OF LIFE 10:00 10: How to pay for orphan drugs: the truth about insurance Michelle Vogel, Executive Director and Founder, Alliance for Patient Advocacy How to collaborate through out of the box approaches Nicole Boice, President, The Global Genes Project How to raise funds and get your disease researched Louis J. DeGennaro, Chief Mission Officer, The Leukemia & Lymphoma Society MANUFACTURING, QUALITY CONTROL AND QUALITY ASSURANCE On-floor seminar day two Thursday, April 11, : How to benefit from disposable technology for orphan drug manufacturing Michiel Ultee, Chief Scientific Officer, Laureate Biopharma How strong science at a small CMO can serve the orphan drug market Abhinav Shukla, Vice President, Process Development and Manufacturing, KBI Biopharma How comparability impacts orphan drug development Thomas G. McCauley, Senior Director, Head of Nonclinical and Bioanalytical Development, Shire Human Genetic Therapies PRINCIPAL INVESTIGATORS AND SCIENTISTS CHALLENGES IN ORPHAN DRUG DISCOVERY How the identification of a mutant gene can result in a new therapy P.J. Brooks, Program Officer, Office of Rare Diseases Research, NCATS, NIH How to get approval - current regulatory and scientific expectations Larissa Lapteva, Deputy Director for Safety, Division of Anesthesia and Analgesia Products, CDER, FDA How to discover orphan drugs through drug repositioning John McKew, Acting Director, NCATS Division of Pre-Clinical Innovation, NIH End of day two

6 2013 sponsors & exhibitors Title sponsor Platinum sponsor Gold sponsors Silver sponsors Other sponsors & exhibitors Contact Sara Torres at or call